U.S. Capital Wealth Advisors’s abrdn Life Sciences Investors HQL Stock Holding History

U.S. Capital Wealth Advisors’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13,000	Closed	-$250K	–	725
2021 Q4	$250K	Buy	13,000 +30	+0.2%	+$604	0.01%	635
2021 Q3	$270K	Buy	+12,970	New	+$278K	0.01%	630

Other funds holding HQL

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

AUB

Atlantic Union Bankshares Glen Allen, Virginia $5.21B AUM 19.46% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

U.S. Capital Wealth Advisors's HQL Position: Q1 2022 in Review

U.S. Capital Wealth Advisors sold out of abrdn Life Sciences Investors (HQL) in Q1 2022, closing a stake of 13,000 shares — an estimated $250K sold.

U.S. Capital Wealth Advisors first reported a position in HQL in Q3 2021 and held it in 2 quarters. The position peaked at $270K in Q3 2021. 66 funds tracked by Wall St. Rank hold HQL as of Q1 2022.

U.S. Capital Wealth Advisors reported no remaining abrdn Life Sciences Investors position as of Q1 2022 after selling out during the quarter.
U.S. Capital Wealth Advisors sold 13,000 abrdn Life Sciences Investors shares in Q1 2022, an estimated $250K.
U.S. Capital Wealth Advisors first reported a position in abrdn Life Sciences Investors in Q3 2021 and held it in 2 quarters.
U.S. Capital Wealth Advisors's abrdn Life Sciences Investors position peaked at $270K in Q3 2021.
66 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2022.

Based on U.S. Capital Wealth Advisors's 13F filing for Q1 2022, filed 12 May 2022.